^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Urothelial Cancer
    Drug:Trodelvy (sacituzumab govitecan-hziy) (Topoisomerase I inhibitor, TROP-2-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Published date:
    04/13/2021
    Excerpt:
    Locally advanced or metastatic urothelial cancer (mUC) who have previously received a platinum-containing chemotherapy and either programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PDL1) inhibitor.
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Immunomedics Press Release
    Title:

    FDA Grants Fast Track Designation to Sacituzumab Govitecan for Metastatic Urothelial Cancer

    Published date:
    04/07/2020
    Excerpt:
    Immunomedics...announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for sacituzumab govitecan for the treatment of adult patients with locally advanced or metastatic urothelial cancer (mUC)...